
Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

Join Drs. Nicola Hanania, Surya Bhatt, and Celeste Porsbjerg for a session exploring the burden of COPD in patients with type 2 inflammation and review key cytokine pathways and Phase 3 data on emerging biologic therapies.
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.
Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.
See how type 2 inflammation underlies remodeling processes in asthma.

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
In this episode, Dr. Sarina Elmariah and Dr. Brian Kim explore prurigo nodularis (PN), with a focus on severe itch, fibrotic skin lesions, and their impact on patients’ quality of life. They discuss PN epidemiology, common comorbidities, and the challenges of managing multimorbid patients, while breaking down the neuroimmune mechanisms, highlighting the role of type 2 cytokines in itch and lesion development.

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.